help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on March 30, 2006, doi:10.1164/rccm.200601-057OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200601-057OCv1
174/1/15    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gauvreau, G. M.
Right arrow Articles by O'Byrne, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gauvreau, G. M.
Right arrow Articles by O'Byrne, P. M.
American Journal of Respiratory and Critical Care Medicine Vol 174. pp. 15-20, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200601-057OC


Original Article

Immunostimulatory Sequences Regulate Interferon-inducible Genes but not Allergic Airway Responses

Gail M. Gauvreau, Edith M. Hessel, Louis-Philippe Boulet, Robert L. Coffman and Paul M. O'Byrne

McMaster University, Hamilton, Ontario; Hopital Laval, Quebec City, Quebec, Canada; and Dynavax Technologies, Berkeley, California

Correspondence and requests for reprints should be addressed to Paul O'Byrne, M.B., HSC 3W10, McMaster University, 1200 Main Street West, Hamilton, ON, Canada, L8N 3Z5. E-mail: obyrnep{at}mcmaster.ca

Rationale: 1018 ISS is a synthetic oligonucleotide containing immunostimulatory CpG motifs. In animal studies, 1018 ISS effectively inhibited Th2-mediated lung inflammation, including eosinophil infiltration, and airway hyperresponsiveness.

Objectives: To evaluate whether 1018 ISS has activity in subjects with allergic asthma.

Methods: Forty subjects (n = 21, 1018 ISS; n = 19, placebo) were enrolled in a randomized, double-blind, placebo-controlled, parallel-group study to examine safety, pharmacologic activity, and efficacy of 1018 ISS on allergen-induced airway responses. Subjects received 36 mg of 1018 ISS or placebo by nebulization weekly for 4 wk.

Measurements: Allergen inhalation challenge was performed 24 h after the 2nd and 4th doses to measure the early and late fall in FEV1. Sputum cells and peripheral blood mononuclear cells were collected before and after dosing, and gene expression was measured by quantitative polymerase chain reaction.

Main Results: Treatment with 1018 ISS significantly increased expression of interferon (IFN)-{gamma} and IFN-inducible genes, such as IFN-{gamma}–inducible 10 kD protein (IP10), monokine induced by IFN-{gamma} (MIG), IFN-stimulated gene (ISG)-54, monocyte chemotactic protein (MCP)-1, and MCP-2 from cells collected postdose (p < 0.05). There was no attenuation of the early or late decrease in FEV1 after 1018 ISS compared with placebo, nor a reduction in allergen-induced sputum eosinophils or Th2-related gene expression measured in sputum cells.

Conclusions: This study demonstrated that 1018 ISS is safe and pharmacologically active in the respiratory tract of asthmatics but, at this dose regimen, did not inhibit a fall in FEV1 or other key features of the response to inhaled allergen challenge. This suggests that induction of IFN and IFN-inducible genes alone is not sufficient to inhibit allergen-induced responses in asthmatic subjects.

Key Words: airway responses • allergen inhalation challenge • allergic asthma • gene expression, immunostimulatory CpG motifs




This article has been cited by other articles:


Home page
J. Immunol.Home page
K. Takeda, S. W. Dow, N. Miyahara, T. Kodama, T. Koya, C. Taube, A. Joetham, J.-W. Park, A. Dakhama, R. M. Kedl, et al.
Vaccine-Induced CD8+ T Cell-Dependent Suppression of Airway Hyperresponsiveness and Inflammation
J. Immunol., July 1, 2009; 183(1): 181 - 190.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. Klinman, H. Shirota, D. Tross, T. Sato, and S. Klaschik
Synthetic oligonucleotides as modulators of inflammation
J. Leukoc. Biol., October 1, 2008; 84(4): 958 - 964.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
O. Tliba and Y. Amrani
Airway Smooth Muscle Cell as an Inflammatory Cell: Lessons Learned from Interferon Signaling Pathways
Proceedings of the ATS, January 1, 2008; 5(1): 106 - 112.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
J. N. Kline
Eat Dirt: CpG DNA and Immunomodulation of Asthma
Proceedings of the ATS, July 1, 2007; 4(3): 283 - 288.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. C. Moore and S. P. Peters
Update in Asthma 2006
Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 649 - 654.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society
  SOTA, FL